Systematic computer-aided disulfide design as a general strategy to stabilize prefusion class I fusion proteins.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 25 03 2024
accepted: 03 07 2024
medline: 8 8 2024
pubmed: 8 8 2024
entrez: 8 8 2024
Statut: epublish

Résumé

Numerous enveloped viruses, such as coronaviruses, influenza, and respiratory syncytial virus (RSV), utilize class I fusion proteins for cell entry. During this process, the proteins transition from a prefusion to a postfusion state, undergoing substantial and irreversible conformational changes. The prefusion conformation has repeatedly shown significant potential in vaccine development. However, the instability of this state poses challenges for its practical application in vaccines. While non-native disulfides have been effective in maintaining the prefusion structure, identifying stabilizing disulfide bonds remains an intricate task. Here, we present a general computational approach to systematically identify prefusion-stabilizing disulfides. Our method assesses the geometric constraints of disulfide bonds and introduces a ranking system to estimate their potential in stabilizing the prefusion conformation. We hypothesized that disulfides restricting the initial stages of the conformational switch could offer higher stability to the prefusion state than those preventing unfolding at a later stage. The implementation of our algorithm on the RSV F protein led to the discovery of prefusion-stabilizing disulfides that supported our hypothesis. Furthermore, the evaluation of our top design as a vaccine candidate in a cotton rat model demonstrated robust protection against RSV infection, highlighting the potential of our approach for vaccine development.

Identifiants

pubmed: 39114655
doi: 10.3389/fimmu.2024.1406929
pmc: PMC11303214
doi:

Substances chimiques

Disulfides 0
Viral Fusion Proteins 0
Respiratory Syncytial Virus Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1406929

Informations de copyright

Copyright © 2024 Gonzalez, Yim, Blanco, Boukhvalova and Strauch.

Déclaration de conflit d'intérêts

Authors KY, JB, and MB were employed by the company Sigmovir Biosystems, Inc. KG and E-MS are inventors of an ongoing US patent application No.18/404,463. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Karen J Gonzalez (KJ)

Institute of Bioinformatics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA, United States.
Department of Medicine, School of Medicine, Washington University, St. Louis, MO, United States.

Kevin C Yim (KC)

Sigmovir Biosystems, Inc., Rockville, MD, United States.

Jorge C G Blanco (JCG)

Sigmovir Biosystems, Inc., Rockville, MD, United States.

Marina S Boukhvalova (MS)

Sigmovir Biosystems, Inc., Rockville, MD, United States.

Eva-Maria Strauch (EM)

Institute of Bioinformatics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA, United States.
Department of Medicine, School of Medicine, Washington University, St. Louis, MO, United States.
Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH